Intyma
Efcacy_and_Safety of_Baricitinib_in Patients_with_Severe_Alopecia
Two Phase 3 Trials of Baricitinib for Alopecia Areata
intyma_monograph
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE AA1 and BRAVE AA2)
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Intyma Monograph